Case Study: Named Patient Program
NPP Delivers Urgent Access to High-Demand Product
13,000 Units. 53 Countries.
The Challenge
A high-demand product had long been requested by physicians worldwide for use across multiple serious and life-threatening conditions, including immune deficiencies, severe infections, hematologic recovery, and emergency response scenarios.
Because the product is not commercially available in many international markets, healthcare providers outside the U.S. frequently required access through Named Patient mechanisms. Demand was reactive, and physician initiated, often arising in urgent clinical situations where treatment alternatives were limited or unavailable.
During periods of heightened global need, manufacturers required a reliable, compliant pathway to fulfill international requests without establishing a full Access Program.
Our Approach
Tanner Pharma supported the manufacturer through its Global Access Program, using a reactive Named Patient supply model to meet real-time international demand. Each request was initiated by a treating physician and assessed by Tanner’s global access specialists to confirm clinical justification, regulatory permissibility, and import feasibility by country. Tanner coordinated:
Regulatory and Named Patient documentation
Import/export and customs coordination
GDP-compliant storage and international distribution
Shipment visibility and delivery confirmation to treating institutions
The product was supplied globally to support physician-led requests, including:
Primary & secondary immune deficiencies
Severe & refractory infections
Hematopoietic recovery & transplant-related use
COVID-era immune support
